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Introduction
The cardiotoxicity of doxorubicin (DOX) and other quinone-containing antitumor anthracyclines has been tentatively attributed to the formation of drug semiquinones which generate superoxide anion and reduce ferritin-bound Fe(III), favoring the release of Fe(II) and its subsequent involvement in free radical reactions. In the present study NADPH-and DOX-supplemented cytosolic fractions from human myocardial biopsies are shown to support a twostep reaction favoring an alternative mechanism of Fe(II) mobilization. The first step is an enzymatic two-electron reduction of the C-13 carbonyl group in the side chain of DOX, yielding a secondary alcohol metabolite which is called doxorubicinol (3.9±0.4 nmoles/mg protein per 4 h, mean±SEM). The second step is a nonenzymatic and superoxide anion-independent redox coupling of a large fraction of doxorubicinol (3.2±0.4 nmol/mg protein per 4 h) with Fe(III) -binding proteins distinct from ferritin, regenerating stoichiometric amounts of DOX, and mobilizing a twofold excess of Fe(ll) ions (6.1±0.7 nmol/mg protein per 4 h).
The formation of secondary alcohol metabolites decreases significantly (P < 0.01) when DOX is replaced by less cardiotoxic anthracyclines such as daunorubicin, 4 '-epi DOX, and 4-demethoxy daunorubicin (2.1±0.1, 1.2±0.2, and 0.6±0.2 nmol/mg protein per 4 h, respectively). Therefore, daunorubicin, 4 '-epi DOX, and 4-demethoxy daunorubicin are significantly (P < 0.01) less The formation of an intracellular pool of free iron can be viewed as a sort of twin-edged sword. Some iron is necessary for cell functions, however, excess iron catalyzes free radical reactions that degrade polyunsaturated fatty acids, proteins, and nucleic acids ( 1, 2) . This dual function of iron is particularly evident with Fe(II), which is more active than Fe(III) in generating hydroxyl radicals, ferryl ions, or equally damaging iron-oxygen complexes (1) . Under physiologic conditions excess Fe(II) is sequestered by ferritin, a shell-shaped multisubunit protein which is placed in the cytosolic milieu and incorporates Fe(III) by oxidizing Fe(II) with oxygen (3) . Ferritin would subsequently release iron only when electron donors accumulate and reduce Fe(III) to Fe(II) (4, 5) . These premises imply that free radical reactions and tissue damage must be preceded by disturbances of ferritin iron movements, resulting in a pathologic process of Fe( II) delocalization. One such process appears to mediate the cardiotoxicity of doxorubicin (DOX),' an anthracycline antibiotic which is active against several tumors but also causes a potentially fatal cardiomyopathy when the cumulative dose exceeds 550 mg/M2 (6) . Clinical studies indicate that the incidence and severity of this cardiotoxicity are significantly lowered by the concurrent administration of dexrazoxane (6, 7) , a bispiperazinedione which hydrolyzes intracellularly and liberates a diacid diamide that chelates iron (8) . The cardioprotective effect of dexrazoxane is nevertheless incomplete (9) , perhaps because a complex of iron with the diacid diamide still generates some fluxes of hydroxyl radicals (10) .
Doxorubicin is comprised of a quinone-containing tetracycline ring and a two-carbon side chain, having a carbonyl moiety at C-13 and a primary alcohol at C-14; an aminosugar (daunosamine) is attached by glycosidic bond to the C-7 of the tetracycline ring (Fig. 1) . In vitro studies have shown that NAD(P)H oxidoreductases of mitochondrial, nuclear, and microsomal membranes support a one electron redox cycling of DOX that may be relevant to the processes of iron delocalization and cardiac damage. In fact, one electron addition to the quinone group forms an unstable semiquinone free radical that regenerates DOX by reducing and releasing iron stored in the femitin core (11, 12) . Under aerobic conditions, the release of Fe(H) is preceded by a redox coupling of DOX semiquinone free radical with oxygen, yielding a superoxide anion (°2-) as the ultimate reductant for ferritin-bound Fe( III) (1 1, 12) . Notewor- thy, cardiomyocytes have relatively little SOD activity as compared with other cell types, mostly because of a selective decrease of the copper-requiring cytosolic enzyme (13). The deficiency in SOD might explain how cardiomyocytes become the targets of a drug which releases Fe(II) by forming 05-.
In vitro and in vivo studies (14) have also shown that the side chain C-13 carbonyl group of DOX is liable to a two electron reduction, yielding a secondary alcohol which is called doxorubicinol (DOXol) (see also Fig. 1 (18) . Perhaps more importantly, the cardiac performance of DOX-treated animals usually decreases at a time when DOXol has reached its maximum intramyocardial concentration (19, 20) , suggesting that this metabolite might be intimately involved in the molecular mechanisms of cardiac damage. Pharmacokinetic studies in DOX-treated animals indicate that cardiac accumulation of DOXol reflects intramyocardial drug metabolism rather than uptake of the metabolite from the blood stream (14, 20, 21 Patients and myocardial samples. Small atrial samples (-0.13 g) were taken from male or female patients undergoing aorto-coronary bypass grafting. Briefly, bioptic fragments of normothermic beating myocardium were taken from the lateral aspect of excluded right atrium before tying the purse string of atrial cannulation. These samples were collected 15-20 min before or 5-10 min after cardiopulmonary bypass (CPB). During CPB, myocardial preservation was obtained by infusion of a St. Thomas Hospital-modified cardioplegic solution (23) . The median age of patients was 58±8 yr (n = 15) or 59±7 yr (n = 25) for the pre-or post-CPB samples, respectively. The biopsies were stored at -80OC until they formed two pools of 2.7 or 4.4 g for the pre-or post-CPB samples, respectively. Larger samples (-3 g) were obtained by recovering right auricolas from a 66-yr-old male and a 64-yr-old female patient undergoing Maze's correction of drug-unresponsive atrial fibrillation (24) . Informed consent was obtained from all patients. Ven (27) . Only 7-deoxy DOX hydroquinone aglycone was formed, in keeping with previous reports that a two electron reduction of the quinone moiety is accompanied by heterolysis of the glycosidic bond between daunosamine and the tetracycline ring (11, 27 ultrafiltration, and loaded onto a (1.3 x 2.5 cm) CNBr-Sepharose 4B column which had been equilibrated with the same buffer. The column had been conjugated with 1 mg of antirecombinant heart-type ferritin (rHF) monoclonal RHO2 IgG, (30) and 1 mg of antirecombinant livertype ferritin (rLF) monoclonal L03 IgG2b (31) . Samples were eluted with 9 ml of the equilibration buffer and the effluent was rechromatographed twice. The final effluent (referred to as "Tris effluent") was concentrated to 1 ml by ultrafiltration and chromatographed on Sepharose 6B as already described for the separation of ferritins from ceruloplasmin. Fractions (0.9 ml) were collected and monitored for absorbance at 280 nm. Protein-containing fractions were subsequently assayed for nonheme iron by reconstituting 0.3-ml aliquots with thioglycolic acid (0.5% vol:vol), bathophenanthroline disulfonate (0.5 mM), and 0.3 M NaCl in a final volume of 0.9 ml. After vigorous mixing, the iron content was determined by measuring the absorbance of the bathophenanthroline-Fe(H) complex at 534 nm. In other experiments, the antiferritin CNBr-Sepharose 4B column was charged with a mixture of self-reconstituted rHF (174 Ag protein -30 nmol iron) and ceruloplasmin-reconstituted rLF (166 ,ug protein -90 nmol of iron). The column was washed with 9 ml equilibration buffer and ferritins were eluted with 4.5 M MgCl2 (32) by monitoring the effluent for absorbance at 280 nm. Fractions with absorbance ("Mg effluent") were pooled, dialyzed extensively against 0.3 M NaCl, and concentrated to 1 ml by ultrafiltration in Centripep 30 (Amicon Corp., Danvers, MA). These samples were eventually chromatographed on Sepharose 6B and analyzed for iron as described for the Tris effluent of cytosols.
Other assays. Spontaneous or cytosol-induced Fe(ll) oxidation was studied in incubations (1 ml final vol) containing FeCl2 (0.5 mM) ±iron-depleted cytosols (3 mg protein/ml) in 0.3 M NaCl, pH 7.0, 37°C. Aliquots (0.1 ml) were taken at regular times and reconstituted with bathophenanthroline disulfonate (0.5 mM) and 0.3 M NaCl, in a final volume of I ml. After mixing, these samples were assayed for absorbance of the bathophenanthroline-Fe(H) complex at 534 nm. The ferric iron content of all cytosol and ferritin preparations was routinely measured using thioglycolic acid as the reductant for Fe(ll1) and batho- (Fig. 3 B) . These results showed that cytosols could incorporate Fe(lI) by oxidizing Fe(II). Taking advantage of this, DOXol formation and Fe(ll) mobilization were measured in NADPH-and DOX-supplemented cytosols which had been reconstituted with increasing amounts of Fe(Ill) by incubating iron-depleted cytosols and Fe(II) for varying lengths of time. As shown in Fig. 4 A, DOXol decreased with increasing the cytosolic content of Fe(lI). By contrast, the mobilization of Fe(II) gradually increased with increasing the Fe(II ) incorporated into the cytosols (Fig. 4 B) . These results confirmed that the enzymatic yield of DOXol was inversely related to the cytosolic content of Fe(IH) and mobilization of Fe(ll) (compare with Fig. 2 and Tables I and   II) . Therefore, we hypothesized that DOXol was consumed during the reductive mobilization of iron. This hypothesis was tested by incubating purified enzymatic DOXol with iron-reconstituted cytosols and by monitoring the fate of DOXol and the mobilization of Fe(II). As shown in Fig. 5 A, DOXol was quantitatively recovered from incubations with iron-depleted cytosols, but it was extensively consumed by cytosols which had been reconstituted with increasing amounts of Fe(III). The ferric iron-dependent loss of DOXol was paralleled by a stoichiometric recovery of DOX and a twofold mobilization of Fe(II) (Fig. 5 B) Step I Step 2 Figure 5 . Doxorubicinol consumption, DOX recovery, and Fe(H) mobilization in iron-depleted or iron-reconstituted cytosols. Iron-reconstituted samples were prepared as described in the legend to Fig. 3 57, 30 , and 15% of the iron released by DOX, respectively (Table IV) . According to Fig.  5 C, iron release might be affected by a decreased formation of C-13 metabolites ( Step 1) and/or by an altered interaction of C-13 metabolites with iron (Step 2). Therefore, the two steps were examined under separate experimental conditions. Step 1 was studied in iron-depleted cytosols, to abrogate redox couplings with Fe(II) and determine the net reduction of DNR, 4 '-epi DOX, and 4-demethoxy DNR to the corresponding secondary alcohols. As shown in Fig. 6 A, DNR, 4 '-epi DOX, and 4-demethoxy DNR were 46, 69, and 84% less susceptible than DOX to an enzymatic reduction at C-13. Step 2 was studied by reconstituting purified enzymatic DNRol, 4'-epi DOXol, and 4-demethoxy DNRol with unmodified cytosols, to evaluate how effectively they redox coupled with cytosolic Fe(III). As shown in Fig. 6 reductively mobilizing a twofold excess of Fe(H). Thus, a specific modification of Step 1 affected iron release by DNR, 4'-epi DOX, and 4-demethoxy DNR.
(e) Comparisons of cytosolic iron with recombinant human ferritins. Three lines of evidence-showed that cytosols were essentially free of ferritin and interacted with iron by virtue of alternate Fe(III)-binding proteins. First, all the Fe(III) ions of unmodified or iron-loaded cytosols could easily pass through an affinity chromatography column which immobilized human rHF and rLF (Table V) . Second, the iron bound to either cytosol (Fig. 7) . And finally, SDS-P showed that the Sepharose 6B fractions with the lacked the M -20,000 and 23,000 bands of fe subunits, respectively (Fig. 7, inset) . It (36, 37) . This inhibition was shown mine serum albuto occur irrespective of a simultaneous addition of iron, hence, e (30,000); soya free radical-independent mechanism was envisioned (36 (42, 43) . Similarly, a positional change in the hydroxyl group at the C-4' of daunosamine (compare with Fig. 1 ) is the sole difference between DOX and 4'-epi DOX, yet, experimental and clinical evidence suggests that 4 '-epi DOX is less cardiotoxic than either DOX or DNR (44) (45) (46) . And finally, deoxydemethylation of the C-4 in the tetracycline ring (compare with Fig. 1 ) converts DNR into a new drug which appears to be the least cardiotoxic among all clinically tested anthracyclines (6, 47) . Structure activity studies in vitro have failed to demonstrate significant differences between equimolar DOX, 4'-epi DOX, DNR, and 4-demethoxy DNR with respect to the redox cycling of the quinone moiety ( 12, 48) and iron release from ferritin (12, 49 Fig. 6 A) . Daunorubicinol, 4'-epi DOXol, and 4-demethoxy DNRol per se would be as effective as DOXol in redox coupling with Fe(III) (Fig. 6 B) . Collectively, these observations indicate that a two electron reduction of the side chain C-13 moiety overshadows the one-electron reduction of the quinone group as a critical determinant of anthracycline metabolism and iron mobilization, irrespective of pharmacokinetic differences that may exist between various analogs.
In an attempt to elucidate the molecular mechanisms underlying the different toxicity of DOX vs DNR, Zweier et al. (51 ) have suggested that a key role might be played by the side chain C-14 moiety. According to these authors, the C-14 primary alcohol of DOX oxidizes at the expense of Fe(III), yielding an aldehyde plus Fe(H) ions which subsequently catalyze free radical reactions (51) . This would explain how DOX is more toxic than DNR or any DNR analog having a C-14 methyl moiety in place of a primary alcohol. Our results do not provide any evidence for the involvement of the C-14 moiety in the reductive mobilization of cytosolic iron. In fact, DOX per se could mobilize as little as one tenth of the iron mobilized upon simultaneous addition of NADPH and enzymatic formation of DOXol (compare with Fig. 2 ). Moreover, we have shown that cytosolic Fe(III) can be reduced to a comparable extent by DOXol, DNRol, 4'-epi DOXol, and 4-demethoxy DNRol, i.e., the C-13 metabolites of anthracyclines which either lack or contain a primary alcohol at C-14. We have no explanation for the exclusive role of the C-13 moiety in Fe(III) reduction. We can only note that the primary alcohol of DOX has been shown to reduce a low-mol-wt acetohydroxamate-Fe(III) complex (51 ), whereas our studies indicate that C-13 secondary alcohols reduce an iron species which is tightly bound to proteins. It is possible that the access to protein-bound iron is limited by sterical requirements that are met by a secondary alcohol at C-13, but not by a primary alcohol at C-14. We should also emphasize that the intracellular concentration of low molecular weight iron is extremely low and difficult to quantify ( 1, 2, 52 ). Hence, a reaction between secondary alcohols and the more abundant protein-bound iron should predominate as a mechanism of cardiotoxicity.
The iron-detoxifying activity of ferritin is the result of a functional cooperation between H and L subunits. The oxygendependent oxidation of Fe(II) occurs predominantly at discrete sites of the H subunits, whereas the size of the cavity which accommodates Fe(III) usually increases with the number of L subunits (3) . Heart ferritin is composed primarily of H subunits, hence, it is particularly well suited for the rapid sequestration of iron. By contrast, liver and spleen ferritins are composed primarily of L subunits and are more suitable for the long-term storage of copious amounts of iron (3, 4) . We have confirmed the existence of these distinct functions for H or L subunits. In fact, H-type recombinant homopolymers were found to oxidatively incorporate greater amounts of iron than did L-type homopolymers devoid of ferroxidase activity (95 vs 32 atoms Fe"'/ molecule per h). However, this difference was reverted by reconstituting ferritins in the presence of ceruloplasmin, which also oxidizes Fe(II) and is frequently used in vitro to incorporate Fe(III) into L-type apoferritins with little ferroxidase activity (2, 53, 54) . In the presence of ceruloplasmin, L-type homopolymers could incorporate much greater amounts of Fe(III) than did H-type homopolymers (260 vs 110 atoms Fe'm/molecule per h), in keeping with a major role for L subunits in the formation of an iron core. In our study, iron-depleted cytosols were shown to oxidize Fe(II) and incorporate Fe(III) in a large excess of that recovered in unmodified samples, in apparent agreement with an H-type ferroxidase activity (compare with Figs. 3, A and B and 7) . Nevertheless, we have provided analytical and functional evidence that: (a) iron was oxidatively incorporated by proteins distinct from ferritin (compare with Fig. 7 and Table V) ; and (b) ferritin did not redox couple with DOXol, irrespective of the subunit composition, the iron:protein ratio, and the presence or absence of ceruloplasmin at the time of iron incorporation into apoferritin (compare with Results, section e). Purified DOXol was also shown not to redox couple with transferrin, irrespective of the degree of iron saturation (see Results, section e). Hence, the DOXol-releasable iron was not accounted for by transferrin which had been released from endocytic vesicles during tissue manipulation and cytosol preparation. These results indicate that the availability of nonferritin sources of Fe(III) represents an additional determinant of the molecular linkage between DOX metabolism and Fe(II) mobilization. The existence of "nonferritin" pools of iron, having variable mol wt and intracellular distribution, has been previously postulated by several research groups (55) (56) (57) (58) (59) (60) . The precise nature and biologic significance of these sources of iron have remained unknown, mostly because of technical difficulties in achieving purification and molecular characterization (55, 60) . It has been tentatively proposed that the nonfemtin pools of iron may serve, upon metabolic needs, for the synthesis of hemeproteins (60) . Alternatively, these pools of iron might identify with enzymes which operate by virtue of essential nonheme Fe(III) moieties (61) . In either case, DOXol-dependent delocalization of these sources of iron would interrupt important cell functions, irrespective of any subsequent involvement of delocalized Fe(II) in free radical reactions and pharmacologic intervention with iron chelators. This scenario might very well provide an additional explanation for the incomplete cardioprotection afforded by dexrazoxane.
In vitro studies with tumor cell lines indicate that anthracycline C-13 metabolites have much less tumoricidal activity than have the parent compounds, with the possible exception of 4-demethoxy DNRol being equipotent as 4-demethoxy DNR (37, 62) . On the other hand, our studies indicate that an intramyocardial mobilization of Fe(II) depends very critically on the formation of C-13 metabolites which reduce Fe(III). This mechanistic dissociation, as well as the clinical need for "better" anthracycline regimens and cardioprotective interventions (6), would possibly identify inhibitors of anthracycline C-13 reductases as a new class of drugs that mitigate cardiotoxicity without affecting antitumor activity. The purification and characterization of intracardiac C-13 reductases would help to select potential inhibitors and accelerate their in vivo testing as cardioprotectants.
